An Open-label, Fixed-sequence, 3-period, 3-treatment, Crossover Study to Assess the Effects of Rifampin on Pharmacokinetics of NKTR-118 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2016
At a glance
- Drugs Naloxegol (Primary) ; Rifampicin
- Indications Constipation; Tuberculosis
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 17 Dec 2015 Results of this and other two trials (see profile 212872 and 217552) were published in the Journal of Clinical Pharmacology
- 11 Dec 2012 Actual end date changed from Jul 2012 to May 2012 as reported by ClinicalTrials.gov.
- 19 Mar 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.